AnaptysBio, Inc. (NASDAQ:ANAB)

CAPS Rating: 5 out of 5 92.18

Caps

How do you think ANAB will perform against the market?

Add Stock to CAPS Watchlist

All Players

26 Outperform
0 Underperform
 

All-Star Players

11 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top ANAB Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

ANAB VS S&P 500 (SPY)

ANAB Summary

Fools bullish on ANAB are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about ANAB.

Recs

0
Member Avatar TMFBlacknGold (94.05) Submitted: 10/24/2018 1:23:39 PM : Outperform Start Price: $76.92 ANAB Score: -2.78

From 9/24/2018:

"AnaptysBio has a promising approach to treating inflammatory diseases, which includes etokimab and one other clinical-stage drug candidate. It also boasts development partnerships with Celgene (inflammation) and Tesaro (oncology).

That said, etokimab will continue to lead the pipeline, and the latest interim data from the phase 2a study in eosinophilic asthma have given investors something to cheer about following the decision to drop the peanut allergy indication. Next up, AnaptysBio will provide follow-up data from day 127 of the asthma trial (likely by the end of the year), and it expects to initiate a phase 2b trial for the indication sometime in 2019. Both events will be important checkpoints for long-term investors."

https://www.fool.com/investing/2018/09/24/heres-why-anaptysbio-inc-rose-as-much-as-185-today.aspx

Recs

0
Member Avatar Bigsef77 (68.18) Submitted: 9/24/2018 1:01:23 PM : Outperform Start Price: $117.36 ANAB Score: -32.52

Here's Why AnaptysBio Inc Rose as Much as 18.5% Today

Shares of AnaptysBio (NASDAQ: ANAB) rose over 18% after the company announced positive top-line data from an ongoing phase 2a trial investigating the potential of its lead drug candidate to treat a severe form of asthma. The therapeutic antibody, etokimab, demonstrated promise in treating severe eosinophilic asthma, which is characterized by severe inflammation and restriction of air pathways in an individual's lungs.

The day after receiving a single dose of etokimab, patients averaged an 8% increase in a measure of lung capacity called forced exhaled volume in one second (FEV1) compared to placebo. That advantage increased to an average improvement of 11% on day 64 of the ongoing trial. No serious adverse events were reported, hinting that the drug candidate is well tolerated.

As of 12:22 p.m. EDT, the stock had settled to a 8.4% gain.

Recs

0
Member Avatar TurksFan (49.99) Submitted: 4/7/2018 8:43:26 AM : Outperform Start Price: $85.86 ANAB Score: -16.87

Starting my research into biotechs

Leaderboard

Find the members with the highest scoring picks in ANAB.

Score Leader

mrmrmrj

mrmrmrj (57.80) Score: +365.30

The Score Leader is the player with the highest score across all their picks in ANAB.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
fclaird 70.42 7/9/2018 Outperform 5Y $72.32 +1.01% -3.65% +4.66 0 Comment
mrmrmrj 57.80 7/23/2018 Outperform 5Y $76.48 -4.48% -4.92% +0.44 0 Comment
Beethzart 57.86 10/16/2018 Outperform 5Y $78.21 -6.60% -4.32% -2.27 0 Comment
TMFBlacknGold 94.05 10/12/2018 Outperform 5Y $76.92 -5.03% -2.26% -2.78 1 Comment
bonjourmesamis 76.80 6/19/2018 Outperform 5Y $79.27 -7.85% -2.75% -5.09 0 Comment
RPMick 87.26 8/30/2018 Outperform 1Y $87.33 -16.35% -8.41% -7.94 0 Comment
TurksFan 49.99 4/9/2018 Outperform 5Y $85.86 -14.92% +1.95% -16.87 1 Comment
cheev 99.96 5/10/2018 Outperform 5Y $90.97 -19.70% -2.10% -17.60 0 Comment
Inept 95.17 4/3/2018 Outperform 5Y $90.40 -19.19% +2.23% -21.42 0 Comment
senminorphil 94.82 4/5/2018 Outperform 5Y $93.88 -22.19% +0.34% -22.53 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ANAB.

Advertisement